key: cord-0336760-rwzae5wa authors: Texis, T.; Cruz-Jaramilllo, J. L.; Garcia-Munoz, W.; Anzures-Cortes, L.; Hadadd-Talancon, L.; Sanchez-Garcia, S.; Jimenez-Martinez, M. d. C.; Perez-Barragan, E.; Nieto-Patlan, A.; Martinez-Ezquerro, J. D.; Rubio-Carrasco, K.; Rodriguez-Dorantes, M.; Cortes-Ramirez, S.; Mellado-Sanchez, G.; Perez-Tapia, S. M.; Gonzalez-Covarrubias, V. title: COVID-19 relevant genetic variants confirmed in an admixed population date: 2022-04-16 journal: nan DOI: 10.1101/2022.04.15.22273925 sha: 861fecb93f9a0190d03fb89503e8833b860ef441 doc_id: 336760 cord_uid: rwzae5wa The dissection of factors that contribute to COVID-19 infection and severity has overwhelmed the scientific community for almost 2 years. Current reports highlight the role of in disease incidence, progression, and severity. Here, we aimed to confirm the presence of previously reported genetic variants in an admixed population. Allele frequencies were assessed and compared between the general population (N=3079) for which at least 30% have not been infected with SARS-CoV2 as per July 2021 versus COVID-19 patients (N=106). Genotyping data from the Illumina GSA array was used to impute genetic variation for 14 COVID-relevant genes, using the 1000G phase 3 as reference based on the human genome assembly hg19, following current standard protocols and recommendations for genetic imputation. Bioinformatic and statistical analyses were performed using MACH v1.0, R, and PLINK. A total of 7953 variants were imputed on, ABO, CCR2, CCR9, CXCR6, DPP9, FYCO1, IL10RB/IFNAR2, LZTFL1, OAS1, OAS2, OAS3, SLC6A20, TYK2, and XCR1. Statistically significant allele differences were reported for 10 and 7 previously identified and confirmed variants, ABO rs657152, DPP9 rs2109069, LZTFL1 rs11385942, OAS1 rs10774671, OAS1 rs2660, OAS2 rs1293767, and OAS3 rs1859330 p<0.03. In addition, we identified 842 variants in these COVID-related genes with significant allele frequency differences between COVID patients and the general population (p-value 0.0001 including the assessment of differences in AF between COVID-19 patients (N=106) and the general population (N=3019) i.e. as described before, we did not include a control group, instead we All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 16, 2022. ; https://doi.org /10.1101 /10. /2022 defined a general population group for which about a third were confirmed as never being infected with SARS-CoV-2 as per September 2021. AF statistical differences were assessed using a Chisquare test considering a threshold of P<0.05, calculations were computed using the Software R v4.0.5. Alternatively, comparisons were also performed exclusively for COVID vs. non-COVID with similar results, but the sample size was significantly reduced and did not benefit the reporting of population allele frequencies. Supplemental Table 1 lists all variants identified on these genes with an allele frequency ≥0.01%. Raw imputation data are available from the corresponding author upon reasonable request. We report allele and genotype frequencies of all variants detected in genomic regions previously associated with COVID-19 (total SNVs=7953. Supplemental Table 1 (Pairo-Castineira et al., 2020b; The Severe Covid-19 GWAS Group, 2020). Next, we compared allele and genotype frequencies between COVID-19 patients and the general population for all 7953 detected variants with a particular focus on those already consistently reported for COVID-19 patients. The group here defined as the general population were on average 58 years of age, showed a BMI of 33 kg/m 2 , 68% were diabetic and 48% hypertensive. The COVID-19 group were on average age 42 years old, 50% were diabetic and 70% hypertensive, 94% of them had a confirmed COVID-19 diagnosis based on a PCR or antigen test. Clinical information for BMI was not available for COVID-19 patients and data for T2D and hypertension has not been completely reported (Table 1 ). Fourteen COVID-19 patients showed severe COVID and required hospitalization, sixteen showed clinically treated moderate symptoms and ten showed mild symptoms, for the remaining patients the medical record has not been completed yet. We imputed 7953 SNVs on 14 genes/loci on chromosomes 3, 9, 12, 19, and 21 with variation that has been consistently associated to COVID-19 in the recent literature (Aydillo, Esther Babady, & Kamboj, 2020a; Initiative, 2020; Kaser, 2020). These loci include COVID-19 related genes, ABO, CCR2, CCR9, CXCR6, DPP9, FYCO1, IL10RB/IFNAR2, LZTFL1, OAS1, OAS2, OAS3, SLC6A20, TYK2, and XCR1. Of the 7953 SNVs imputed, 3696 were detected in Mexican Mestizos i.e., variants with at least one alternative allele. Common variation i.e., an allele frequency > 0.01 was observed for 2645 variants in both study groups and most SNVs showed allele frequency of: mean:0.0663, median 0.002, range 0.00016-0.500, (Supplemental Table 1 ). When comparing AF between COVID-19 samples versus the general population (N=106 vs. 3019), we confirmed the statistical significance of 7 out of 10 variants that have been previously All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 16, 2022. ; https://doi.org /10.1101 /10. /2022 associated to COVID-19 infection and severe disease, rs657152, rs1859330, rs1293767, rs10774671, rs2660, rs2109069, rs11385942. Variants, rs8176747, rs2285932, and rs2236757, did not show relevant allele frequency differences in our group comparisons despite being reported as COVID-19 related, i.e., seven of ten variants previously associated to COVID-19 were confirmed in this study showing significant AF differences in COVID-19 patients versus the general population (Table 2) . Additional to the comparisons on previously reported variants, we identified 13 SNVs on these regions with apparent and significant AF differences between COVID-19 patients and the general population. The most relevant differences were found on CXCR6, FYCO1, NRBF2P2, XCR1, ABO, OAS3, and DPP9 for the latter we observed linkage disequilibrium on rs72977997 and rs118149076, (Table 2) all variants and AF can be found in Supplemental Table 1 . Interestingly 43 variants showed an AF of zero in the general population (N=3079) but were present in COVID patients i.e., 43 variants showed the reference or "wild type" genotype in the general population but were homozygous or heterozygous in COVID-19 samples. Of these ABO rs56390333 (AF=0.076) and FYCO1 rs200040076 (AF=0.132) showed the most significant differences in AF with 5 and 11 with a homozygous genotype in COVID-19 samples respectively (p-value=E-179, and E-62, Table 2 ). Other genes that also showed variation exclusively in COVID patients were, CCR9 (9 SNVs), OAS2 (3 SNVs), LZTFL1 (12 SNVs), SLC6A20 (8 SNVs), IFNAR2, DPP9, and IL10RB, the latter three with one SNV each, statistical significance ranged from p-value < E-8 to E-46 (Supplemental Table 1 ). Next, we compared allele and genotype frequencies between COVID-19 patients and the general population for all variants with an AF>0, rs2109069 the above SNVs did not comply with Hardy-Weinberg equilibrium p<0.003. Reports by the Severe COVID-19 GWAS and the GenOMICC groups included the above-mentioned variants All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 16, 2022. ; https://doi.org /10.1101 /10. /2022 for which we identified AF differences in COVID-19 samples but for the three remaining of the 10 sought loci here, ABO rs8176747, IFNAR2 rs2236757, OAS3 rs2285932, we did not observe significant AF differences (Table 3) . Supplemental Table 1 includes a full list of genetic variants and AF differences. In addition to confirming previous results, we identified over 100 variants with significant AF differences between the general population and COVID-19 patients (Table 3) (Heo et al., 2014) , these variants have no previous reports. Summarizing, this last All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 16, 2022. ; https://doi.org /10.1101 /10. /2022 analysis showed 287 and 734 potentially protective or deleterious variants on 14 COVID-related genes. Since 2019, SARS-CoV-2 infection has shown several waves which in some countries have been buffered by vaccination (Zheng et al., 2022) . COVID-19 presents an unpredictable course from asymptomatic, mild, or moderate symptoms, to serious complications and 5.5 million deaths. Similar to other viral diseases certain comorbidities are well known to worsen the outcome. COVID-19 patients have an increased risk to be hospitalized if diabetic, hypertensive, or obese. According to the WHO and the Institutional Repository for Information Sharing (IRIS), Mexicans, compared to other countries show an increased COVID-19 risk that ranges from 25-fold for 0.2% of the population to 1.2-fold for 18% of the country's population (www.iris.paho.org). And although there is no clear protocol to define who is at a specific risk for SARS-CoV-2 infection, defining a genetic predisposition together with clinical and environmental factors could improve diagnosis, treatment, and the development of preventive interventions for high-risk groups potentially using genotype-based diagnosis. Scientific efforts are trying to underpin these genetic and non-genetic factors currently contributing to the collection of data to better depict the disease and to direct personalized care in the years to come. An interesting review by Z. Yildirim et al. noted that for certain populations higher COVID-19 incidence cannot be explained by behavior, environment, vitamin D levels, socioeconomic status, and cardiovascular risk, but that there is an apparent familial clustering of severity, prompting to genetic variants that could be shared or private for certain ethnic groups (Yildirim et al., 2021) . In this study we aimed to assess the allele frequency of variants on 14 COVID-related genes in Mexican Mestizos, and to compare these frequencies between the general population and confirmed COVID-19 patients. At the time of our analysis GWAS analyses have reported 14 genetic loci associated to COVID-19, ABO, SLC6A20, LZTFL1, CCR9, FYCO1, CXR6, XCR1, CCR2, OAS1-3, TYK2, DPP9, IL10RB/IFNAR2 several of these have been confirmed by other research groups (Anastassopoulou, Gkizarioti, Patrinos, & Tsakris, 2020; Callaway, 2021; Dite et al., 2021b; K Niemi et al., 2021; Velavan et al., 2021) , so we focused our investigation on these loci. We identified and observed AF differences for seven previously reported variants, the most statistically relevant for this analysis were variants TYK2 rs74956615, IFNAR2 rs2236757, DPP9 rs2109069 and those on OAS1-3 (Table 2 ). These variants have not been yet defined as causal of SARS-CoV-2 infection or severity, but it is known that they play a relevant role in the immune All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 16, 2022. ; https://doi.org /10.1101 /10. /2022 response (Velavan et al., 2021) . IFNAR as part of interferons receptor conveys antiviral immunity, TYK2, tyrosine kinase 2 is part of the effector cascade of activated interferon receptors, increases susceptibility to microbial infections and has been recently suggested as a drug target (K Niemi et al., 2021; Pairo-Castineira et al., 2020b) , DPP9 codes for a dipeptidyl peptidase from the family of serine proteases similar to DPP4 also known as CD26 that prompts T cell activation. Genetic variants on both genes DPP4 and DPP9 (ex. rs13015258 and rs2109069) have been associated with severe COVID-19 (Asgari & Pousaz, 2021; Yildirim et al., 2021) . Finally, OAS1-3 genes are considered "antiviral" as their products trigger viral mRNA degradation and are induced by interferons. Variants on these genes and its classification on affecting the immune system may only be useful to appropriately direct patients infected with SARS-Co-V2, as research has shown that specific variation on immunity genes may represent risk for one disease but protection for another, as it happened for the CCR5 mutation that protects against HIV but increases the risk for West Nile virus infection (Glass et al., 2005) . Inflammation and inflammaging, immunosuppression, and genetically immunodeficient are terms depicting COVID-19 severe cases. For example, inflammaging results from the chronic stimulation of the innate immune system with a high damaging impact during aging, it is a common and conserved mechanism of metabolic diseases in the elderly (Dall'Olio et al., 2013; Franceschi, Garagnani, Parini, Giuliani, & Santoro, 2018) . Current research ought to identify and dissect genetic variants that associate with these altered-immune stages of the disease and to better define immunodeficiency in genetic terms which will complement the proper identification of patients at risk for severe COVID-19. Initial reports on the genetics of severe COVID-19 prompted almost immediately to blood type, suggesting that while type O may offer some protection against SARS-CoV-2 infection, types A and B may be present in patients at risk, but this failed to replicate in several studies (Latz et al., 2020) . The Severe COVID-19 group reported ABO variants, rs8176747, rs657152, and rs41302905 significantly associated to severe COVID-19 (Zhao et al., 2021) , for the two former we did not observed allele frequency differences when comparing groups. Nevertheless, we identified 157 variants on ABO with significant AF differences (p-value <0.01). Among those we observed ABO rs657152-A differing significantly between COVID-19 patients and the general population (AF: 0.3632 in COVID vs. 0.2436, p-value=5.25E-05), this variant has been associated with risk of deep-vein thrombosis and pulmonary embolism, conditions present in patients with severe COVID-19 (Aydillo, Esther Babady, & Kamboj, 2020b). Our observations may support current reports addressing the lack of a consistent association between ABO blood types and disease severity, which may warrant delving into a comprehensive consideration of the ABO All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 16, 2022. system and its relation to viral infection, immunogenetics, and disease (Fleeson et al., 2017; Latz et al., 2020; Paul et al., 2021; Zhang, Bastard, Liu, et al., 2020) . We observed a lack of confirmation on gene variants previously reported to play a role in the immunity against COVID-19 and antiviral defense (Zeberg & Pääbo, 2021b; Zhang, Bastard, Bolze, et al., 2020) for IFNAR rs2236757, ABO rs8176747, and OAS3 rs2285932, which did not show significant allele frequency differences. IFNAR rs2236757 showed an AF:0.456 in COVID-19 patients and 0.439 in the general population. This variant is globally frequent in Asians (AF:0.630) and Caucasians (AF:0.300). Castineira et al reported a 1.3 OR towards increased COVID severity when the variant is present, putatively affecting antiviral defense mechanisms, organ damage, and inflammation. For ABO rs8176747, previous reports indicate a higher frequency in affected patients, we also observed a 40% higher AF in COVID patients, but here differences did not reach statistical significance. Intronic Neandertal-derived OAS1 rs4766664 and OAS3 rs2285932 identified in the GenOMICC study (Pairo-Castineira et al., 2020b; Zeberg & Pääbo, 2020) did not reach statistical significance in our comparisons. Both SNVs showed a lower AF in COVID-19 patients which are lower than AF values reported in Mexicans from Los Angeles suggesting that its protective trait may not be present in this study population. It is possible that for these three previously COVID-19 associated variants the small size of our COVID group is hindering allele frequency differences, or that haplotypes are not in full LD in this admixed population. Despite the absence of replicating results for the three above mentioned variants we observed significant AF differences on over 100 variants including, four on ABO p-value